Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie.
Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G; American Society of Clinical Psychopharmacology; Pharmakopsychiatrie TTDMTFOTAFNU. Schoretsanitis G, et al. Among authors: haen e. J Clin Psychiatry. 2020 May 19;81(3):19cs13169. doi: 10.4088/JCP.19cs13169. J Clin Psychiatry. 2020. PMID: 32433836 Free article.
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.
Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Rüther E, Paulzen M, Haen E, Hiemke C, Timm J, Gründer G; NeSSy Study Group. Veselinović T, et al. Among authors: haen e. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):550-560. doi: 10.1097/JCP.0000000000001131. J Clin Psychopharmacol. 2019. PMID: 31688449 Clinical Trial.
Pharmacokinetic patterns of risperidone-associated adverse drug reactions.
Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M. Schoretsanitis G, et al. Among authors: haen e. Eur J Clin Pharmacol. 2016 Sep;72(9):1091-8. doi: 10.1007/s00228-016-2085-2. Epub 2016 Jul 4. Eur J Clin Pharmacol. 2016. PMID: 27376639 Free article.
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics.
Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KRJ, Walther S, Lammertz SE, Haen E. Paulzen M, et al. Among authors: haen e. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:101-106. doi: 10.1016/j.pnpbp.2017.03.002. Epub 2017 Mar 14. Prog Neuropsychopharmacol Biol Psychiatry. 2017. PMID: 28302501
128 results